The U.S. Food and Drug Administration last week pushed its self-declared deadline for rendering an approval decision on the
drug Bydureon to Oct. 22. The previous deadline was in March.
Indianapolis-based drugmaker Eli Lilly and Co. is on course to cut 5,500 jobs by the end of 2011 in a bid to eliminate $1
billion in annual expenses.
The deal included a $296 million criminal fine, but no charges against executives who failed to properly report problems with the company's defibrillators.
There has been a noticeable uptick in the level of health care real estate development activity this year.
Companion Diagnostics wants to detect early warning signs of chronic diseases.
Medco, which operates a major pharmacy and distribution center in Whitestown, got a boost from higher prices on brand-name
drugs and from greater sales of more profitable generic drugs.
Clarian is planning to spend $1.7 billion in the next five years on capital projects, half of that going to its downtown Indianapolis
campuses.
Work force reductions, new business structure make leased office space unnecessary. Moves will begin in late June.
Once-weekly form of Byetta is awaiting the FDA’s OK. Analyst predict the new version of the drug, if approved, could rack
up sales of $2 billion annually.
Louisiana was one of 13 states that filed individual suits in state courts over allegations that Lilly pushed Zyprexa for
uses that had not been approved by federal regulators.
Relocating operations to an existing plant in Canton, Ga., will result in the loss of 130 jobs.
Eli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version
of the cancer drug Gemzar until November.
Eli Lilly and Co.’s Alimta has received the preliminary backing of a United Kingdom agency as a maintenance treatment for
patients with the most common form of lung cancer.
The Batesville-based medical equipment supplier said it expects the cuts to save the company about $16 million a year.
Lilly’s lobbying spending represents a 36-percent drop from the final quarter of 2008, even though the Congressional debate
over health care reform peaked during the last quarter of 2009.
Deal with unit of Massachusetts-based Thermo Fisher Scientific would keep many of the employees working in same
location.
Eli Lilly is interested in assets that may be offered for sale as a result of Sanofi-Aventis SA and Merck & Co.’s plan to
combine their veterinary units.
Sweeping changes phase in slowly for most, but insurers, hospitals, drug companies, employers, workers, medical device makers
and more will eventually feel impact.
Drugmakers and insurers could gain millions of customers under the legislation, but the industry also will pay new fees and
face stricter rules that may shrink profit and fuel mergers.
To pay for the changes, the legislation includes more than $400 billion in higher taxes over a decade, roughly half of it
from a new Medicare payroll tax on individuals with incomes over $200,000 and couples over $250,000.
